文献速递卫生政策与健康促进免疫规划

疫苗的标签外使用

Off-label use of vaccines.
PubMed 文献 · Vaccine · 2017-03-22

本文综述疫苗标签外推荐与使用,重点比较监管机构批准的说明书与国家和国际公共卫生咨询机构的使用建议之间的差异。差异源于上市后数据和获益风险分析,可能导致接种者和受种者困惑并降低依从性;作者提出通过要求生产商定期更新说明书来减少标签外使用。

要点

  • 公共卫生建议与产品说明书在疫苗使用上可能存在差异,造成接种者和受种者困惑。
  • 说明书可能因初始许可时缺乏对照试验安全性证据而限制特定人群接种,而公共卫生机构可基于上市后数据推荐。
  • 作者建议要求生产商定期根据新证据调整说明书,以减少疫苗标签外使用。

核心结论

  • 公共卫生建议与产品说明书之间的差异可能导致接种者和受种者困惑,并可能降低对国家疫苗接种规划的依从性。
  • 作者提出通过要求生产商定期根据公共卫生需求和新证据调整说明书来减少疫苗标签外使用。
  • 监管机构在要求特定目标人群的额外上市后数据方面可发挥关键作用。

研究设计与样本

  • 本文为综述,聚焦疫苗的标签外推荐与使用,比较监管机构批准的说明书与国家和国际公共卫生咨询机构的使用建议之间的差异。

主要发现

  • 在许多国家,说明书可能包含针对特定人群(如孕妇)的监管限制和警告,原因是疫苗初始许可时缺乏对照试验的安全性证据。
  • 公共卫生机构可能基于额外的上市后数据和获益风险分析,推荐同一疫苗用于该人群。

临床怎么用

  • 当公共卫生建议涉及说明书适应症之外的疫苗使用时,监管机构、公共卫生机构、公司和卫生保健提供者或接种者之间的良好沟通至关重要。
  • 建议以及说明书和说明书变更应基于证据。
  • 差异的理由和推荐的疫苗标签外使用应传达给提供者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article reviews the off-label recommendations and use of vaccines, and focuses on the differences between the labelled instructions on how to use the vaccine as approved by the regulatory authorities (or "label"1), and the recommendations for use issued by public health advisory bodies at national and international levels. Differences between public health recommendations and the product label regarding the vaccine use can lead to confusion at the level of vaccinators and vaccinees and possibly result in lower compliance with national vaccination schedules. In particular, in many countries, the label may contain regulatory restrictions and warnings against vaccination of specific population groups (e.g. pregnant women) due to a lack of evidence of safety from controlled trials at the time of initial licensure of the vaccine, while public health authorities may recommend the same vaccine for that group, based on additional post-marketing data and benefit risk analyses. We provide an overview of the different responsibilities between regulatory authorities and public health advisory bodies, and the rationale for off-label use2 of vaccines, the challenges involved based on the impact of off-label use in real-life. We propose to reduce off-label use of vaccines by requiring the manufacturer to regularly adapt the label as much as possible to the public health needs as supported by new evidence. This would require manufacturers to collect and report post-marketing data, communicate them to all stakeholders and regulators to extrapolate existing evidence (when acceptable) to other groups or to other brands of a vaccine (class effect3). Regulatory authorities have a key role to play by requesting additional post-marketing data, e.g. in specific target groups. When public health recommendations for vaccine use that are outside labelled indications are considered necessary, good communication between regulatory bodies, public health authorities, companies and health care providers or vaccinators is crucial. Recommendations as well as labels and label changes should be evidence-based. The rationale for the discrepancy and the recommended off-label use of a vaccine should be communicated to providers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Neels P, Southern J, Abramson J, et al. Off-label use of vaccines. Vaccine. 2017. PMID: 28341112. doi:10.1016/j.vaccine.2017.02.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。